Our team is composed of engineers, scientists and clinicians with deep roots in ophthalmic devices and drug delivery.
We take ideas from inception through regulatory approval. We have active projects addressing unmet needs in cataract / lens replacement surgery and other chronic ophthalmic diseases.
We value partnerships that will lead to paradigm shifts in global eye care.
Co-Founder and President
Dr. Kahook is a practicing ophthalmologist and serial entrepreneur with 15 years of startup and academic experience in research and development. Six of his devices are currently in human trials or commercialized for clinical use. ClarVista Medical, acquired by Alcon in 2017, developed an advanced modular intraoc
Co-Founder and President
Dr. Kahook is a practicing ophthalmologist and serial entrepreneur with 15 years of startup and academic experience in research and development. Six of his devices are currently in human trials or commercialized for clinical use. ClarVista Medical, acquired by Alcon in 2017, developed an advanced modular intraocular lens system co-invented by Dr. Kahook. He is the inventor of the Kahook Dual Blade, which is marketed globally by New World Medical. Dr. Kahook is also an inventor of the VERUS Capsulorhexis Device and ShapeTech’s shape memory polymer intraocular lens material, which was licensed by Johnson & Johnson Vision. His inventions have been the focus of over $100 million in venture backed funding and industry led development and commercialization since 2008 and his devices have treated well over 100 thousand patients globally.
Co-Founder and CEO
Glenn Sussman is a serial inventor and entrepreneur with 30+ years of experience in the ophthalmic space. Prior to co-founding SpyGlass Ophthalmics, he was responsible for the development of a novel IOL for ClarVista Medical which was acquired by Alcon in 2017. Glenn previously served in an R&D leadership role at Alcon
Co-Founder and CEO
Glenn Sussman is a serial inventor and entrepreneur with 30+ years of experience in the ophthalmic space. Prior to co-founding SpyGlass Ophthalmics, he was responsible for the development of a novel IOL for ClarVista Medical which was acquired by Alcon in 2017. Glenn previously served in an R&D leadership role at Alcon for 18 years. He has supported and led development for several other industry leaders and academic facilities. Glenn has over 60 issued US patents in areas that range from intraocular lenses to surgical devices for ophthalmic surgery.
General Manager
James Dennewill brings over 20 years of medical device industry experience, specializing in the development of products, people and processes required to bring new technologies to market. Prior to SpyGlass Ophthalmics, he spent over six years with Cianna Medical (now part of Merit Medical), where he held various positions o
General Manager
James Dennewill brings over 20 years of medical device industry experience, specializing in the development of products, people and processes required to bring new technologies to market. Prior to SpyGlass Ophthalmics, he spent over six years with Cianna Medical (now part of Merit Medical), where he held various positions of escalating responsibility including VP of Operations and COO. James also spent over 10 years with Med-Logics, Inc., where he managed the development of ophthalmic products, resulting in a range of U.S. and international patents, and served as Management Representative for all regulatory affairs.
James earned his bachelor’s degree in Financial Management and Operations Management at California State University, Long Beach and holds an MBA from the Yale School of Management.
Copyright © 2019 SpyGlass Ophthalmics - All Rights Reserved.
Powered by GoDaddy Website Builder